Published in Gene Therapy Weekly, October 12th, 1998
Two firms are ready to find out, and the potential stakes are enormous. Ten to 20 percent of U.S. residents - 26 to 55 million potential customers - get the flu every year.
The drugs are effective against both influenza A and influenza B, the major circulating virus strains. Both drugs attack the influenza neuraminidase enzyme, essential for the virus to spread from one infected cell to another.
"Neuraminidase inhibitors should provide significant advances in the management of influenza virus infections," concluded Frederick G. Hayden of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.